Wells Fargo Starts Coverage on Arcellx with Bullish Outlook
Wells Fargo initiates coverage of Arcellx with an Overweight rating and a $100 price target, citing strong potential for its CAR-T therapy anito-cel in multiple myeloma.
/ 3 items
#ACLX↓
Anito-cel Shows High Efficacy and Impressive Two-Year Survival Rates in Relapsed/Refractory Multiple Myeloma
New data confirms Arcellx’s anito-cel is a powerful and safe CAR-T cell therapy for relapsed or refractory multiple myeloma, showing deep, durable responses.
Arcellx Stock Dips on Kelonia's Early CAR-T Data: Analyst Calls Reaction "Overdone"
Guggenheim analyst says Arcellx stock decline is overdone after competitor Kelonia released early Phase 1 CAR-T therapy data. Maintains Buy rating despite market pressure.